
Unicycive Therapeutics (UNCY) Stock Forecast & Price Target
Unicycive Therapeutics (UNCY) Analyst Ratings
Bulls say
Unicycive Therapeutics is attractive fundamentally because the FDA has raised no efficacy or safety concerns for oxylanthanum carbonate, and the latest NDA resubmission shifted the remaining issue toward a more addressable manufacturing/compliance fix using a new third-party vendor with a March 2024 NAI inspection and 12-month stability data. The company also has meaningful commercial leverage if approved, since TDAPA could pay at 100% of ASP for two years outside the ESRD bundle, with modeling pointing to FY2027 revenue of $27.5M and risk-adjusted FY27/FY28 revenues of $102M/$399M alongside peak U.S. net sales near $400M in 2028E. Financially, cash and marketable securities of $61.4M and runway into 2H27 reduce near-term financing pressure, while the clean balance sheet and warrant milestones support upside if FDA inspection and approval timelines improve.
Bears say
Unicycive Therapeutics is a clinical-stage biotech with no product revenue and a history of significant operating losses, leaving it unlikely to reach GAAP profitability or positive cash flow until 2027 and dependent on external funding. Its balance sheet is stretched, with about $61M in cash at the end of 2Q 2026 and $102M in warrant commitments, but those tranches could add up to 15.8M shares of dilution while still not eliminating the need for more capital. The investment case also hinges on OLC overcoming binary FDA, manufacturing, reimbursement, and commercial adoption risks, while delayed approval to late 2026 and slower TDAPA timing to mid 2027 imply a more uncertain and potentially weaker sales ramp.
This aggregate rating is based on analysts' research of Unicycive Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Unicycive Therapeutics (UNCY) Analyst Forecast & Price Prediction
Start investing in Unicycive Therapeutics (UNCY)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Unicycive Therapeutics (UNCY) Forecast
Unicycive Therapeutics (UNCY) Analyst Forecast & Price Prediction
Start investing in Unicycive Therapeutics (UNCY)
Order type
Buy in
Order amount
Est. shares
0 shares